Google AI
The Times Australia
The Times World News

.

What's available and how to get them

  • Written by Nial Wheate, Associate Professor of the Sydney Pharmacy School, University of Sydney
what's available and how to get them

With COVID case numbers expected to rise[1] in Australia over the coming weeks and months there is significant concern the numbers of severely sick patients may overwhelm hospitals.

Thankfully, over time we are learning more about COVID[2] and now have a range of medicines that are effective in treating it, including antivirals.

Which medicine a patient receives, if they even need one at all, will depend on the severity of their symptoms and whether they have any underlying health problems.

Read more: How are Australia and NZ managing the rising COVID winter wave – and is either getting it right?[3]

Here is what we have in our COVID arsenal

When the COVID pandemic began, we didn’t have any drugs to treat the virus. Instead, we had to rely on drugs that could treat COVID symptoms while the body healed itself.

Now we have a range of recommended COVID medicines[4] that are either antivirals or antibody-based drugs. These are suitable for both hospitalised and at-home patients and include lagevrio[5], remdesivir[6], paxlovid[7], evusheld[8] and sotrovimab[9].

In Australia, there are other antibody drugs available but they are not currently widely used. This includes ronapreve[10], which is less effective[11] against the omicron strain of the virus, and regkirona[12] which is still being explored in clinical trials[13].

Other drugs are also used for COVID but, again, they don’t treat the virus. Instead they are mostly used to reduce inflammation in the lungs.

These medicines have all been shown to work in human clinical trials and are either fully or provisionally approved by the Australian Therapeutic Goods Administration[14] for the treatment of COVID.

Each COVID medicine works in a different way. Evusheld and sotrovimab comprise antibody molecules that neutralise the virus and block its entry into human cells, whereas paxlovid works by stopping a key enzyme the virus needs to replicate. Both lagevrio and remdesivir work by getting incorporated into the virus’ genetic material and causing mutations to stop the virus from replicating.

Paxlovid and lagevrio come in tablet form while remdesivir, sotrovimab, and evusheld come as injections that need to be administered by a doctor.

older man sick in bed with tissue
Who you are and whether you are at home or in hospital will determine your treatment. Shutterstock[15]

Read more: Australia approves two new medicines in the fight against COVID. How can you get them and are they effective against Omicron?[16]

The right drug for the right patient

Clinical guidelines[17] direct health staff as to which drug they need to administer to each patient.

Most people who test positive for COVID will not need treatment with an antiviral drug, as current COVID variants tend to induce mild symptoms that can be managed with rest and isolation at home.

For some patients managing COVID at home, certain health factors mean their doctor will prescribe a COVID drug. This includes people who have a poor functioning immune system, those who are not vaccinated or are not up-to-date with vaccinations, and those who are at a high risk of severe disease.

These risk factors[18] include respiratory conditions such as asthma, cardiovascular diseases including high blood pressure, obesity, diabetes and kidney failure.

Where you’re treated

If a patient is sick enough to need hospitalisation, specialist doctors will decide if and what COVID drug to prescribe.

If a COVID drug is needed for an at-home patient both lagevrio and paxlovid are available on the Pharmaceutical Benefits Scheme (PBS)[19] for specific people[20] including those over 70, or those over 50 who have one of the risk factors mentioned earlier.

Immunocompromised people over the age of 18, and people who identify as Aboriginal or Torres Strait Islander origin who are over 30 and at high risk, are also eligible for PBS-subsidised lagevrio or paxlovid.

These drugs can be prescribed by a general practitioner (GP) and accessed through a local community pharmacy. If a patient is not able to see their GP in person, a COVID drug can be prescribed by booking a telehealth appointment[21] with a doctor. The drug can then be delivered to their home from their local pharmacy. Importantly, these drugs must be started within five days of symptom onset[22].

In some instances an at-home COVID patient may require an injection-only drug such as remdesivir or evusheld, which are only available through the patient’s local hospital network. Sotrovimab is another COVID drug that is only administered in healthcare facilities. This is because patients need to be monitored after they receive the infusion. General practitioners will refer their patients to a local hospital for these treatments.

Read more: I have mild COVID – should I take the antiviral Paxlovid?[23]

What about side effects?

All medicines have side effects, even common medications like paracetamol and aspirin.

If patients do experience side effects, these are likely to be specific to the drug being taken. Some of the possible side effects of lagevrio[24] include mild to moderate diarrhoea, nausea and dizziness in less than 2% of those trialled.

For paxlovid[25], side effects can include changes in taste, diarrhoea, headache, and vomiting. Serious side effects, which affect fewer than 2% of patients[26], include liver problems which can cause prolonged nausea or vomiting, loss of appetite, stomach pain, yellowing eyes or skin, and dark urine[27].

Some of the side effects of remdesivir[28] include rash, sweating, fever, shortness of breath, swelling, changes in blood pressure or heart rate, nausea, and shivering.

Patients who experience side effects while taking a COVID drug should see their doctor if they are concerned. If a patient experiences any severe side effects, such as signs of liver problems, then they should call their doctor immediately or go straight to their local hospital.

References

  1. ^ COVID case numbers expected to rise (www.abc.net.au)
  2. ^ we are learning more about COVID (theconversation.com)
  3. ^ How are Australia and NZ managing the rising COVID winter wave – and is either getting it right? (theconversation.com)
  4. ^ recommended COVID medicines (www.health.gov.au)
  5. ^ lagevrio (www.nps.org.au)
  6. ^ remdesivir (www.nps.org.au)
  7. ^ paxlovid (www.tga.gov.au)
  8. ^ evusheld (www.health.gov.au)
  9. ^ sotrovimab (www.fda.gov)
  10. ^ ronapreve (www.tga.gov.au)
  11. ^ less effective (covid19evidence.net.au)
  12. ^ regkirona (www.tga.gov.au)
  13. ^ clinical trials (app.magicapp.org)
  14. ^ Therapeutic Goods Administration (tga.gov.au)
  15. ^ Shutterstock (image.shutterstock.com)
  16. ^ Australia approves two new medicines in the fight against COVID. How can you get them and are they effective against Omicron? (theconversation.com)
  17. ^ Clinical guidelines (covid19evidence.net.au)
  18. ^ risk factors (www.health.gov.au)
  19. ^ lagevrio and paxlovid are available on the Pharmaceutical Benefits Scheme (PBS) (www.health.gov.au)
  20. ^ specific people (www.pbs.gov.au)
  21. ^ telehealth appointment (www.health.gov.au)
  22. ^ five days of symptom onset (www.tga.gov.au)
  23. ^ I have mild COVID – should I take the antiviral Paxlovid? (theconversation.com)
  24. ^ lagevrio (www.nps.org.au)
  25. ^ paxlovid (www.nps.org.au)
  26. ^ fewer than 2% of patients (www.tga.gov.au)
  27. ^ dark urine (www.webmd.com)
  28. ^ side effects of remdesivir (www.ebs.tga.gov.au)

Read more https://theconversation.com/covid-drugs-in-australia-whats-available-and-how-to-get-them-186907

Times Magazine

CRO Tech Stack: A Technical Guide to Conversion Rate Optimization Tools

The fascinating thing is that the value of this website lies in the fact that creating a high-cali...

How Decentralised Applications Are Reshaping Enterprise Software in Australia

Australian businesses are experiencing a quiet revolution in how they manage data, execute agreeme...

Bambu Lab P2S 3D Printer Review: High-End Performance Meets Everyday Usability

After a full month of hands-on testing, the Bambu Lab P2S 3D printer has proven itself to be one...

Nearly Half of Disadvantaged Australian Schools Run Libraries on Less Than $1000 a Year

A new national snapshot from Dymocks Children’s Charities reveals outdated books, no librarians ...

Growing EV popularity is leading to queues at fast chargers. Could a kerbside charger network help?

The war on Iran has made crystal clear how shaky our reliance on fossil fuels is. It’s no surpri...

TRUCKIES UNDER THE PUMP AS FUEL PRICES BECOME TWO THIRDS OF OPERATING COSTS FOR SOME BUSINESS OWNERS

As Australia’s fuel crisis continues, truck drivers across the nation are being hit hard despite t...

The Times Features

Mortgage Lending in Australia: Brokers vs Banks — Trust…

For most Australians, taking out a mortgage is the single largest financial decision they will e...

Building Costs in Australia: Permits, Taxes, Contributi…

Australia’s housing debate is often framed around supply and demand, interest rates, and populat...

Airfares: What the Iran Disarmament Campaign Means for …

For Australians planning their next interstate getaway or long-awaited overseas holiday, the cos...

Interest-free loans needed for agriculture amid fuel cr…

The Albanese Government should release the details of its plan to provide interest-free loans to b...

Next stage of works to modernise Port of Devonport

TasPorts is progressing the next stage of its QuayLink program at the Port of Devonport, with up...

‘Cuddle therapy’ sounds like what we all need right now…

Cuddle therapy is having a moment[1]. The idea for this emerging therapy is for you to book in...

The Decentralized DJ: How Play House is Rewriting the M…

The traditional music industry model is currently facing its most significant challenge since the ...

What Australians Use YouTube For

In Australia, YouTube is no longer just a video platform—it is infrastructure. It entertains, e...

Independent MPs warn NDIS funding cuts risk leaving vul…

Federal Independent MPs have called on the Albanese Government to provide greater transparency...